Form 4 for INSM INSMED Inc
Accepted 2026-06-26 16:03:40 ET · period of report 2026-06-25 · accession 0001402051-26-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-26 16:03 | 2026-06-25 | INSM | Lewis William | COB, CEO, Dir | M - OptEx | $24.94 | +21.4K | 280.3K | +8% | +$533.7K |
| DMT | 2026-06-26 16:03 | 2026-06-25 | INSM | Lewis William | COB, CEO, Dir | S - Sale+OE | $103.32 | -21.4K | 258.9K | -8% | -$2.21M |
| DMT | 2026-06-26 16:03 | 2026-06-25 | INSM | Lewis William | COB, CEO, Dir | M - OptEx | $0.00 | -21.4K | 8,880 | -71% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-25 | M | A | 12,518 | $30.46 | 271,435 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-06-25 | M | A | 8,880 | $17.16 | 280,315 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 3 | Common | Common Stock | 2026-06-25 | S | D | 12,091 | $102.34 | 268,224 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 12,091 shares sold at prices ranging from $101.78 to $102.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2026-06-25 | S | D | 1,836 | $103.10 | 266,388 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) This is the weighted average sales price representing 1,836 shares sold at prices ranging from $102.78 to $103.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Common | Common Stock | 2026-06-25 | S | D | 3,723 | $104.28 | 262,665 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) This is the weighted average sales price representing 3,723 shares sold at prices ranging from $103.87 to $104.75 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 6 | Common | Common Stock | 2026-06-25 | S | D | 2,456 | $105.27 | 260,209 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F5) This is the weighted average sales price representing 2,456 shares sold at prices ranging from $104.90 to $105.88 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 7 | Common | Common Stock | 2026-06-25 | S | D | 1,292 | $106.27 | 258,917 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F6) This is the weighted average sales price representing 1,292 shares sold at prices ranging from $105.90 to $106.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 8 | Derivative | Stock Option (right to buy) | 2026-06-25 | M | D | 12,518 | $0.00 | 12,519 | D | $30.46 · — to 2028-01-04 | 12,518 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F7) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 9 | Derivative | Stock Option (right to buy) | 2026-06-25 | M | D | 8,880 | $0.00 | 8,880 | D | $17.16 · — to 2027-05-17 | 8,880 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F7) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |